102 related articles for article (PubMed ID: 27043079)
1. Rapid COJEC Induction Therapy for High-risk Neuroblastoma Patients - Cochrane Review.
Peinemann F; van Dalen EC; Berthold F
Klin Padiatr; 2016 Apr; 228(3):130-4. PubMed ID: 27043079
[TBL] [Abstract][Full Text] [Related]
2. Rapid COJEC versus standard induction therapies for high-risk neuroblastoma.
Peinemann F; Tushabe DA; van Dalen EC; Berthold F
Cochrane Database Syst Rev; 2015 May; 2015(5):CD010774. PubMed ID: 25989478
[TBL] [Abstract][Full Text] [Related]
3. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial.
Pearson AD; Pinkerton CR; Lewis IJ; Imeson J; Ellershaw C; Machin D; ;
Lancet Oncol; 2008 Mar; 9(3):247-56. PubMed ID: 18308250
[TBL] [Abstract][Full Text] [Related]
4. Percentage tumor necrosis following chemotherapy in neuroblastoma correlates with MYCN status but not survival.
Bomken S; Davies B; Chong L; Cole M; Wood KM; McDermott M; Tweddle DA
Pediatr Hematol Oncol; 2011 Mar; 28(2):106-14. PubMed ID: 21214410
[TBL] [Abstract][Full Text] [Related]
5. Randomized Trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the European HR-NBL1/SIOPEN study.
Ladenstein R; Valteau-Couanet D; Brock P; Yaniv I; Castel V; Laureys G; Malis J; Papadakis V; Lacerda A; Ruud E; Kogner P; Garami M; Balwierz W; Schroeder H; Beck-Popovic M; Schreier G; Machin D; Pötschger U; Pearson A
J Clin Oncol; 2010 Jul; 28(21):3516-24. PubMed ID: 20567002
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes and prognostic factors to predict treatment response in high risk neuroblastoma patients receiving topotecan and cyclophosphamide containing induction regimen: a prospective multicenter study.
Rujkijyanont P; Photia A; Traivaree C; Monsereenusorn C; Anurathapan U; Seksarn P; Sosothikul D; Techavichit P; Sanpakit K; Phuakpet K; Wiangnon S; Chotsampancharoen T; Chainansamit SO; Kanjanapongkul S; Meekaewkunchorn A; Hongeng S
BMC Cancer; 2019 Oct; 19(1):961. PubMed ID: 31619207
[TBL] [Abstract][Full Text] [Related]
7. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
8. A nationwide phase II study of delayed local treatment for children with high-risk neuroblastoma: The Japan Children's Cancer Group Neuroblastoma Committee Trial JN-H-11.
Yoneda A; Shichino H; Hishiki T; Matsumoto K; Ohira M; Kamijo T; Kuroda T; Soejima T; Nakazawa A; Takimoto T; Yokota I; Teramukai S; Takahashi H; Fukushima T; Hara J; Kaneko M; Ikeda H; Tajiri T; Mugishima H; Nakagawara A
Pediatr Blood Cancer; 2024 Jun; 71(6):e30976. PubMed ID: 38577760
[TBL] [Abstract][Full Text] [Related]
9. OPEC/OJEC for stage 4 neuroblastoma in children over 1 year of age.
Tweddle DA; Pinkerton CR; Lewis IJ; Ellershaw C; Cole M; Pearson AD
Med Pediatr Oncol; 2001 Jan; 36(1):239-42. PubMed ID: 11464894
[TBL] [Abstract][Full Text] [Related]
10. Retinoic Acid for High-risk Neuroblastoma Patients after Autologous Stem Cell Transplantation - Cochrane Review.
Peinemann F; van Dalen EC; Berthold F
Klin Padiatr; 2016 Apr; 228(3):124-9. PubMed ID: 27011226
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up.
Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Hatlevoll R; Dahle R; Boye N; Wang M; Vigander T; Vilsvik J; Skovlund E; Hannisdal E; Aamdal S;
J Clin Oncol; 2002 Dec; 20(24):4665-72. PubMed ID: 12488411
[TBL] [Abstract][Full Text] [Related]
12. Phase II investigational window using carboplatin, iproplatin, ifosfamide, and epirubicin in children with untreated disseminated neuroblastoma: a Pediatric Oncology Group study.
Castleberry RP; Cantor AB; Green AA; Joshi V; Berkow RL; Buchanan GR; Leventhal B; Mahoney DH; Smith EI; Hayes FA
J Clin Oncol; 1994 Aug; 12(8):1616-20. PubMed ID: 8040674
[TBL] [Abstract][Full Text] [Related]
13. Topotecan-Vincristine-Doxorubicin in Stage 4 High-Risk Neuroblastoma Patients Failing to Achieve a Complete Metastatic Response to Rapid COJEC: A SIOPEN Study.
Amoroso L; Erminio G; Makin G; Pearson ADJ; Brock P; Valteau-Couanet D; Castel V; Pasquet M; Laureys G; Thomas C; Luksch R; Ladenstein R; Haupt R; Garaventa A;
Cancer Res Treat; 2018 Jan; 50(1):148-155. PubMed ID: 28324923
[TBL] [Abstract][Full Text] [Related]
14. Role of chemotherapy resistance genes in outcome of neuroblastoma.
de Cremoux P; Jourdan-Da-Silva N; Couturier J; Tran-Perennou C; Schleiermacher G; Fehlbaum P; Doz F; Mosseri V; Delattre O; Klijanienko J; Vielh P; Michon J
Pediatr Blood Cancer; 2007 Mar; 48(3):311-7. PubMed ID: 16609945
[TBL] [Abstract][Full Text] [Related]
15. [Evaluation of efficacy of treatment for 30 children with neuroblastoma].
Sun XF; Liu DG; Su YS; Lin TY; Chen XQ; He YJ
Ai Zheng; 2003 Dec; 22(12):1343-5. PubMed ID: 14693065
[TBL] [Abstract][Full Text] [Related]
16. Results of induction chemotherapy in children older than 1 year with a stage 4 neuroblastoma treated with the NB 97 French Society of Pediatric Oncology (SFOP) protocol.
Valteau-Couanet D; Michon J; Boneu A; Rodary C; Perel Y; Bergeron C; Rubie H; Coze C; Plantaz D; Bernard F; Chastagner P; Bouzy J; Hartmann O
J Clin Oncol; 2005 Jan; 23(3):532-40. PubMed ID: 15659499
[TBL] [Abstract][Full Text] [Related]
17. Treatment of advanced neuroblastoma in children over 1 year of age: the critical role of ¹³¹I-metaiodobenzylguanidine combined with chemotherapy in a rapid induction regimen.
Mastrangelo S; Rufini V; Ruggiero A; Di Giannatale A; Riccardi R
Pediatr Blood Cancer; 2011 Jul; 56(7):1032-40. PubMed ID: 21344615
[TBL] [Abstract][Full Text] [Related]
18. Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age.
Kushner BH; LaQuaglia MP; Bonilla MA; Lindsley K; Rosenfield N; Yeh S; Eddy J; Gerald WL; Heller G; Cheung NK
J Clin Oncol; 1994 Dec; 12(12):2607-13. PubMed ID: 7527454
[TBL] [Abstract][Full Text] [Related]
19. Image-defined risk factor assessment of neurogenic tumors after neoadjuvant chemotherapy is useful for predicting intra-operative risk factors and the completeness of resection.
Irtan S; Brisse HJ; Minard-Colin V; Schleiermacher G; Galmiche-Rolland L; Le Cossec C; Elie C; Canale S; Michon J; Valteau-Couanet D; Sarnacki S
Pediatr Blood Cancer; 2015 Sep; 62(9):1543-9. PubMed ID: 25820608
[TBL] [Abstract][Full Text] [Related]
20. Long-term analysis of children with metastatic neuroblastoma treated in the ENSG5 randomised clinical trial.
Moreno L; Vaidya SJ; Schrey D; Pinkerton CR; Lewis IJ; Kearns PR; Machin D; Pearson ADJ;
Pediatr Blood Cancer; 2019 Apr; 66(4):e27565. PubMed ID: 30516328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]